Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

shutterstock_124071745_resized for siteThird Quarter 2015 Financial Results

Genmab reported its Third Quarter 2015 financial results and held an investor conference call regarding the results on November 3. Click the following links to access the archived call: Click here to listen to the webcast. Click here to download the podcast. Click here to download slides. 

Dec 8_website 150x110 

Genmab's 2015 R&D Update

Genmab will host its R&D Update on December 8, 2015 at 14.00-16.00 Eastern time (20.00 CET/19.00 GMT). The event will take place at the Hyatt Regency Orlando in Orlando, Florida. The seminar will include data from studies with the Company's antibodies presented at the 2015 American Society of Hematology Annual Meeting (December 5-8) plus additional progress with proprietary technologies and products in Genmab's pipeline. Click here if you would like to attend. A webcast of the event will also be available on Genmab's website.

Our Technologies Explained

Learn about Genmab’s proprietary cutting edge technologies, the DuoBody® and HexaBody® platforms at our new technology website